partial AUCs for locally acting MR [Design Issues]

posted by jag009  – NJ, 2020-12-05 08:01 (87 d 15:38 ago) – Posting: # 22116
Views: 495

Hi,

» I’m involved in the development of a MR generic drug that is locally acting in the GI tract. Despite the very helpful new EMA guideline (Guideline on equivalence studies for the demonstration of therapeutic equivalence for locally applied, locally acting products in the gastrointestinal tract, CPMP/EWP/239/95 Rev. 1, Corr.1*) I´m struggling with designing the BE studies to support submission in EU.
»
» Most problematic is the justification of the cut-off for the required partial AUCs.

Something like this in US for mesalamine ER?

https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_022301.pdf

J

Complete thread:

Activity
 Admin contact
21,359 posts in 4,460 threads, 1,492 registered users;
online 5 (0 registered, 5 guests [including 1 identified bots]).
Forum time: Tuesday 23:40 CET (Europe/Vienna)

The interpretation of facts in a certain way
stimulates other scientists’ thoughts.    Róbert Bárány

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5